Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology

Autor: Lathuiliere, Aurelien, Vernet, Remi, Charrier, Emily, Urwyler, Muriel, Von Rohr, Olivier, Belkouch, Marie-Claude, Saingier, Valentin, Bouvarel, Thomas, Guillarme, Davy, Engel, Adrien, Salmon, Patrick, Laumonier, Thomas, Grogg, Julien, Mach, Nicolas

Publikováno v: In Molecular Therapy - Methods & Clinical Development 8 September 2022 26:441-458

N-acetylglucosamine supplementation fails to bypass the critical acetylation of glucosamine-6-phosphate required for Toxoplasma gondii replication and invasion.

Autor: Alberione, María Pía, González-Ruiz, Víctor, von Rohr, Olivier, Rudaz, Serge, Soldati-Favre, Dominique, Izquierdo, Luis, Kloehn, Joachim

Publikováno v: PLoS Pathogens; 6/20/2024, Vol. 20 Issue 6, p1-27, 27p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P-190 Personalized Immunotherapy with Cell-Encapsulation Technology for 2nd line R/M HNSCC: Safety and Early Efficacy Data from all HNSCC patients treated with MVX-ONCO-1 in two clinical trials

Autor: Fernandez, Eugenio, Vernet, Remi, Charrier, Emily, Joerger, Markus, de Belkouch, Marie-Clau, Urwyler, Muriel, von Rohr, Olivier, Rubin, Olivier, Villard, Jean, Ancrenaz, Virginie, Grandjean, Nicole, Lavallière, Emmanuel, Lafferma, Elisabeth, Grogg, Julien, Mach, Nicolas

Publikováno v: In Oral Oncology July 2021 118 Supplement:6-6

A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors.

Autor: Vernet R; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Fernandez E; Department of Oncology, Geneva University Hospitals and Medical School, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Migliorini D; Department of Oncology, Geneva University Hospitals and Medical School, Geneva, Switzerland.; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Agora Cancer Research Center, Lausanne, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Ancrenaz V; Department of Oncology, Geneva University Hospitals and Medical School, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Charrier E; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland.; MaxiVAX SA, Geneva, Switzerland., Belkouch MC; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Von Rohr O; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., Urwyler M; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland., De Vito C; Division of Clinical Pathology, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland., Renaux J; MaxiVAX SA, Geneva, Switzerland., Villard J; Clinical Cell Therapy Lab, Geneva University Hospital, Geneva, Switzerland., Rubin O; Clinical Cell Therapy Lab, Geneva University Hospital, Geneva, Switzerland., Grogg J; MaxiVAX SA, Geneva, Switzerland., Mach N; Department of Oncology, Geneva University Hospitals and Medical School, Geneva, Switzerland.; Centre for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.; Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Aug 01; Vol. 4 (8), pp. 2089-2100.